Sage Therapeutics Inc

SAGE

Equity

ISIN US78667J1088 / Valor 24747713

NASDAQ (2025-04-08)

USD 6.39-4.05%

Sage Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Sage Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative medicines to treat brain health disorders. The company has made significant strides in addressing maternal mental health by bringing to market the only FDA-approved treatments for postpartum depression. Beyond maternal mental health, Sage Therapeutics is also working on pioneering treatments for other brain health issues, including essential tremor and cognitive impairment associated with neurodegenerative diseases. By integrating patient and care partner perspectives throughout the research and commercialization processes, Sage aims to meet the unmet needs within the realm of brain health disorders, striving to make a meaningful impact on millions of lives by viewing and treating brain health through a new lens.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Sage Therapeutics Inc. reported total revenues of $11.9 million for the third quarter of 2024, a significant increase from $2.7 million in the same quarter of 2023. This growth was primarily driven by collaboration revenue related to ZURZUVAE, which amounted to $11 million.

Operating Expenses

For the third quarter of 2024, Sage Therapeutics Inc. incurred total operating costs and expenses of $113.1 million, a decrease from $214.6 million in the third quarter of 2023. This reduction reflects the company's efforts to streamline operations and focus on key strategic areas.

Net Loss

Sage Therapeutics Inc. reported a net loss of $93.6 million for the third quarter of 2024, compared to a net loss of $201.6 million in the same period of 2023. The decrease in net loss is attributed to increased revenues and reduced operating expenses.

Cash Position

As of September 30, 2024, Sage Therapeutics Inc. had cash, cash equivalents, and marketable securities totaling $569 million. This represents a decrease from $753.2 million at the end of 2023, reflecting the company's ongoing investments in its pipeline and strategic initiatives.

Financial Outlook

Sage Therapeutics Inc. anticipates that its existing cash, cash equivalents, and marketable securities, along with anticipated funding from collaborations, will support its operations into 2026. The company plans to update its cash runway guidance in the near future, considering potential savings from its recent reorganization.

Summarized from source with an LLMView Source

Key figures

-61.5%1Y

-82.5%3Y

-78.7%5Y

Performance

75.6%1Y

76.5%3Y

70.6%5Y

Volatility